Iovance Biotherapeutics, Inc. (IOVA)
NGM – Real Time Price. Currency in USD
6.56
+0.07 (1.08%)
Market open: Aug 12, 2026, 12:20 PM EDT
6.43
-0.06 (-0.92%)
Previous after-hours: Aug 11, 2026, 7:57 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
6.56
+0.07 (1.08%)
Market open: Aug 12, 2026, 12:20 PM EDT
6.43
-0.06 (-0.92%)
Previous after-hours: Aug 11, 2026, 7:57 PM EDT
No Data
There are no news for this stock.
Total debt $46.0M significantly exceeds cash reserves ($6.0M), raising financial stability concerns
Total current assets $464.3M exceed Total current liabilities $106.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$66.3M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.34 | 6.05 | 10 | |
| Quick ratio | 3.82 | 5.63 | 10 | |
| Debt to Equity | 0.06 | 0.30 | 9.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | 1M | 164M | 264M | 325M |
| Gross Profit | -21M | -32M | 18M | 54M | 121M |
| Operating Income | -399M | -461M | -395M | -398M | -296M |
| Net Income | -396M | -444M | -372M | -391M | -290M |
| EBITDA | -378M | -427M | -352M | -351M | -252M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 61.59 | 63.14 | 10 |
| Next quarter | 41.95 | 43.96 | 10 |
| Current year | 51.73 | 55.3 | 10 |
| Next year | 35.55 | 46.08 | 10 |
| Weighted average score | 10 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 39.04 | 40.14 | 42.11 | 15.76 | 9.8 |
| Y/Y | 65.65 | 57.63 | 66.67 | 11.52 | 9.3 |
| 3y average | 4919.53 | -0.33 | 23.74 | -3.25 | 5.5 |
| 5y average | 3351.32 | -9.69 | 8.19 | -6.61 | 4.5 |
| Weighted average score | 7.3 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |